MichaelWerner NikolausDeiningerMD
Hematology • Milwaukee, WIHematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Professor, Internal Medicine, University of Utah School of Medicine
Dr. Deininger is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8701 W Watertown Plank Rd
Milwaukee, WI 53226Phone+1 414-955-8246
Education & Training
University of Wurzburg Faculty of MedicineClass of 1990
Certifications & Licensure
CT State Medical License Current
WI State Medical License 2022 - 2025
OR State Medical License 2008 - 2023
UT State Medical License 2010 - 2022
Publications & Presentations
PubMed
- 251 citationsBCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.Matthew S. Zabriskie, Christopher A. Eide, Srinivas K. Tantravahi, Nadeem A. Vellore, Johanna Estrada
Cancer Cell. 2014-09-08 - 16 citationsAsciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results.Michael J Mauro, Timothy P Hughes, Dong-Wook Kim, Delphine Rea, Jorge E Cortes
Leukemia. 2023-05-01 - 286 citationsTyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid LeukemiaJavid Moslehi, Michael W. Deininger
Journal of Clinical Oncology. 2015-09-14
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
